Navis Wealth Advisors LLC boosted its holdings in shares of SPDR S&P Biotech ETF (NYSEARCA:XBI – Free Report) by 87.5% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 4,500 shares of the exchange traded fund’s stock after acquiring an additional 2,100 shares during the period. Navis Wealth Advisors LLC’s holdings in SPDR S&P Biotech ETF were worth $405,000 at the end of the most recent reporting period.
A number of other large investors also recently bought and sold shares of the business. Healthcare of Ontario Pension Plan Trust Fund lifted its position in SPDR S&P Biotech ETF by 198.6% during the 3rd quarter. Healthcare of Ontario Pension Plan Trust Fund now owns 9,229,000 shares of the exchange traded fund’s stock valued at $911,825,000 after acquiring an additional 6,138,000 shares during the period. Clal Insurance Enterprises Holdings Ltd purchased a new position in SPDR S&P Biotech ETF during the 3rd quarter valued at about $141,284,000. Northwestern Mutual Wealth Management Co. lifted its position in SPDR S&P Biotech ETF by 1.6% during the 2nd quarter. Northwestern Mutual Wealth Management Co. now owns 1,145,049 shares of the exchange traded fund’s stock valued at $106,158,000 after acquiring an additional 18,202 shares during the period. Mirae Asset Securities USA Inc. lifted its position in SPDR S&P Biotech ETF by 50.0% during the 3rd quarter. Mirae Asset Securities USA Inc. now owns 900,000 shares of the exchange traded fund’s stock valued at $88,920,000 after acquiring an additional 300,000 shares during the period. Finally, Main Management Fund Advisors LLC raised its holdings in SPDR S&P Biotech ETF by 8.3% in the second quarter. Main Management Fund Advisors LLC now owns 598,200 shares of the exchange traded fund’s stock worth $55,459,000 after buying an additional 45,700 shares during the last quarter.
SPDR S&P Biotech ETF Stock Performance
Shares of SPDR S&P Biotech ETF stock opened at $92.46 on Friday. The stock has a market capitalization of $7.05 billion, a PE ratio of 11.47 and a beta of 1.11. SPDR S&P Biotech ETF has a 52-week low of $81.14 and a 52-week high of $105.47. The company has a 50-day simple moving average of $93.34 and a two-hundred day simple moving average of $96.89.
About SPDR S&P Biotech ETF
SPDR S&P Biotech ETF (the Fund) seeks to closely match the returns and characteristics of the S&P Biotechnology Select Industry Index. The S&P Biotechnology Select Industry Index represents the biotechnology sub-industry portion of the S&P Total Markets Index. The S&P TMI tracks all the United States common stocks listed on the New York Stock Exchange, American Stock Exchange, National Association of Securities Dealers Automated Quotation (NASDAQ) National Market and NASDAQ Small Cap exchanges.
See Also
- Five stocks we like better than SPDR S&P Biotech ETF
- What is the FTSE 100 index?
- MP Materials: Rare Earth Elements Powering the EV Boom
- Why Invest in 5G? How to Invest in 5G Stocks
- Verizon’s Turnaround Gains Traction: New Highs Are Likely in 2025
- The Significance of a Trillion-Dollar Market Cap Goes Beyond a Number
- Bloom Energy: Powering the Future With Decentralized Energy
Want to see what other hedge funds are holding XBI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for SPDR S&P Biotech ETF (NYSEARCA:XBI – Free Report).
Receive News & Ratings for SPDR S&P Biotech ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SPDR S&P Biotech ETF and related companies with MarketBeat.com's FREE daily email newsletter.